2019
PTEN loss is associated with resistance to cetuximab in patients with head and neck squamous cell carcinoma
Eze N, Lee JW, Yang DH, Zhu F, Neumeister V, Sandoval-Schaefer T, Mehra R, Ridge JA, Forastiere A, Chung CH, Burtness B. PTEN loss is associated with resistance to cetuximab in patients with head and neck squamous cell carcinoma. Oral Oncology 2019, 91: 69-78. PMID: 30926065, PMCID: PMC6855599, DOI: 10.1016/j.oraloncology.2019.02.026.Peer-Reviewed Original ResearchConceptsNeck squamous cell carcinomaEpidermal growth factor receptorSquamous cell carcinomaCell carcinomaCetuximab-based therapyTrial of cisplatinTrials (RCTs) of cetuximabPotential predictive biomarkersPTEN expressionLack of benefitPI3K mutationsPI3K p110αHigh PTEN expressionPI3K pathwayGrowth factor receptorHot spot mutationsStandard therapySuperior PFSMultivariable analysisPredictive biomarkersLoss of expressionSuch therapyCommon abnormalityCetuximabSide effects
2017
The risk of level IB nodal involvement in oropharynx cancer: Guidance for submandibular gland sparing irradiation
Lee NCJ, Kelly JR, Park HS, Yarbrough WG, Burtness BA, Husain ZA. The risk of level IB nodal involvement in oropharynx cancer: Guidance for submandibular gland sparing irradiation. Practical Radiation Oncology 2017, 7: e317-e321. PMID: 28356201, DOI: 10.1016/j.prro.2017.02.004.Peer-Reviewed Original ResearchMeSH KeywordsCarcinoma, Squamous CellFemaleHead and Neck NeoplasmsHumansLymph Node ExcisionLymph NodesLymphatic MetastasisMaleMiddle AgedNeoplasm StagingOrgan Sparing TreatmentsOropharyngeal NeoplasmsPapillomaviridaeParotid GlandRadiotherapy, AdjuvantRetrospective StudiesSquamous Cell Carcinoma of Head and NeckSubmandibular GlandXerostomiaConceptsOropharyngeal squamous cell cancerPositive nodesNodal involvementLevel Ib lymph nodesIb lymph nodesPrimary surgical treatmentRetrospective chart reviewCohort of patientsCommon side effectsSquamous cell cancerIpsilateral neckNodal dissectionOropharynx cancerChart reviewNeck irradiationLymph nodesSurgical treatmentCell cancerLevel IbNodal stationsNegative imagingRadiation therapyLower riskSide effectsPatients
2015
Head and Neck Cancers, Version 1.2015.
Pfister DG, Spencer S, Brizel DM, Burtness B, Busse PM, Caudell JJ, Cmelak AJ, Colevas AD, Dunphy F, Eisele DW, Foote RL, Gilbert J, Gillison ML, Haddad RI, Haughey BH, Hicks WL, Hitchcock YJ, Jimeno A, Kies MS, Lydiatt WM, Maghami E, McCaffrey T, Mell LK, Mittal BB, Pinto HA, Ridge JA, Rodriguez CP, Samant S, Shah JP, Weber RS, Wolf GT, Worden F, Yom SS, McMillian N, Hughes M. Head and Neck Cancers, Version 1.2015. Journal Of The National Comprehensive Cancer Network 2015, 13: 847-55; quiz 856. PMID: 26150579, PMCID: PMC4976490, DOI: 10.6004/jnccn.2015.0102.Peer-Reviewed Original Research
2014
Targeted agents: management of dermatologic toxicities.
Burtness B. Targeted agents: management of dermatologic toxicities. Journal Of The National Comprehensive Cancer Network 2014, 12: 793-6. PMID: 24853219, DOI: 10.6004/jnccn.2014.0192.Peer-Reviewed Original ResearchConceptsEpidermal growth factor receptor inhibitorsGrowth factor receptor inhibitorsDermatologic side effectsQuality of lifeDermatologic toxicitiesCutaneous complicationsSkin complicationsTherapeutic mainstayReceptor inhibitorsCommon culpritsToxicity profileMTOR inhibitorsSide effectsCosmetic issuesAnticancer treatmentPotential infectionComplicationsTreatmentInhibitorsTherapyAgentsCancerInfectionMainstayBRAF
2010
Antibody-Based Therapies for Solid Tumors
Shanbhag S, Burtness B. Antibody-Based Therapies for Solid Tumors. Cancer Growth And Progression 2010, 245-256. DOI: 10.1007/978-90-481-9704-0_13.Peer-Reviewed Original ResearchSide effectsHER2-overexpressing breast cancerStandard cytotoxic chemotherapyCell lung cancerEGFR antibody cetuximabAntibody-based therapiesExcess side effectsAnti-VEGF antibodyMechanism of actionMetastatic settingCytotoxic chemotherapyMetastatic colorectalLung cancerColorectal carcinomaBreast cancerAntibody cetuximabVEGF antibodySolid tumorsAntibody trastuzumabClinical useMonoclonal antibodiesCancer therapeuticsCancerAntibodiesBevacizumab
2005
Oxaliplatin Induces a Delayed Immune-Mediated Hemolytic Anemia: A Case Report and Review of the Literature
Noronha V, Burtness B, Murren J, Duffy TP. Oxaliplatin Induces a Delayed Immune-Mediated Hemolytic Anemia: A Case Report and Review of the Literature. Clinical Colorectal Cancer 2005, 5: 283-286. PMID: 16356307, DOI: 10.3816/ccc.2005.n.041.Peer-Reviewed Original ResearchMeSH KeywordsAnemia, HemolyticAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsBevacizumabCecal NeoplasmsDrug HypersensitivityFemaleFluorouracilHumansHypersensitivity, DelayedIleal NeoplasmsIntestinal NeoplasmsLeucovorinMiddle AgedOrganoplatinum CompoundsOxaliplatinTreatment OutcomeConceptsHemolytic anemiaMild self-limited episodesCycles of chemotherapySelf-limited episodesImmune-mediated hemolysisMinimal side effectsBevacizumab therapyPartial remissionLaboratory featuresIleocecal regionMetastatic carcinomaCase reportFuture therapiesSide effectsAnemiaOxaliplatinTherapyRemissionChemotherapyCarcinomaSymptomsImmuneWomen
2002
Phase I Study of Perillyl Alcohol in Patients with Refractory Malignancies
Murren JR, Pizzorno G, DiStasio SA, McKeon A, Peccerillo K, Gollerkari A, McMurray W, Burtness BA, Rutherford T, Li X, Ho PT, Sartorelli A. Phase I Study of Perillyl Alcohol in Patients with Refractory Malignancies. Cancer Biology & Therapy 2002, 1: 130-135. PMID: 12170772, DOI: 10.4161/cbt.57.Peer-Reviewed Original ResearchConceptsPeak plasma concentrationPlasma concentrationsChronic basisDihydroperillic acidMean peak plasma concentrationLow-grade nauseaPerillyl alcoholStabilization of diseaseGastrointestinal side effectsH post ingestionPerillic acidMonoterpene perillyl alcoholStarting doseRefractory malignanciesPost ingestionSide effectsPatientsMajor metabolitePharmacokinetic studyDoseMicroMNauseaMalignancyAverage numberDisease
2000
Dose escalation and pharmacokinetic study of irinotecan in combination with paclitaxel in patients with advanced cancer
Murren J, Peccerillo K, DiStasio S, Li X, Leffert J, Pizzorno G, Burtness B, McKeon A, Cheng Y. Dose escalation and pharmacokinetic study of irinotecan in combination with paclitaxel in patients with advanced cancer. Cancer Chemotherapy And Pharmacology 2000, 46: 43-50. PMID: 10912577, DOI: 10.1007/s002800000115.Peer-Reviewed Original ResearchConceptsDose of irinotecanElimination of irinotecanDrug AdministrationAdvanced cancerFirst cycle patientsChemotherapy-related toxicityDose of paclitaxelClinical side effectsSequence of administrationBlood cell elementsNonhematologic toxicityReversible neutropeniaFirst doseMost patientsPartial responseCycle patientsDose escalationMild diarrheaPreclinical dataPlasma concentrationsSide effectsIrinotecanPatientsPharmacokinetic parametersWeekly schedule